DALLAS, Texas and REDWOOD CITY, Calif., June 01, 2023 (GLOBE NEWSWIRE) -- Mark Cuban Cost Plus Drug Company, PBC (“Cost Plus Drugs” or “Mark Cuban Cost Plus Drug Company”) and Coherus BioSciences, Inc ...
RxPreferred's inclusion of YUSIMRY™ will have a significant impact on employer-sponsored health plans and their members with the biosimilar representing a 92% discount from the list price for Humira®.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback